Licata, Luca http://orcid.org/0000-0002-0331-3585
Barreca, Marco
Galbardi, Barbara
Dugo, Matteo
Viale, Giulia
Győrffy, Balàzs
Karn, Thomas http://orcid.org/0000-0002-3264-6573
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Gianni, Luca
Callari, Maurizio http://orcid.org/0000-0001-5239-0918
Bianchini, Giampaolo http://orcid.org/0000-0002-6790-6267
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG2018 - ID21787)
Breast Cancer Research Foundation
Article History
Received: 20 July 2023
Revised: 10 October 2023
Accepted: 18 October 2023
First Online: 7 November 2023
Competing interests
: LL has served on the advisory boards for: Lilly, Exact Sciences, AstraZeneca, Italfarmaco and Daiichi Sankyo; has received consulting fees from: Exact Sciences and Helsinn; honoraria for speakers’ bureaus from: Gilead, Exact Sciences and EISAI; support for travel, accommodations, expenses from: Lilly and Gilead. GV has served on the advisory boards for Gilead; has received honoraria for speakers’ bureaus from Novartis, Lilly; support for travel, accommodations, and expenses from: Lilly and Pfizer. TK reports a patent for EP18209672 is pending. LP has received consulting fees and honoraria from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. LG has received consulting fees/has served on the advisory boards for: Roche, Pfizer, AstraZeneca, Merck Sharp & Dohme, Synaffix, Celgene, Lilly, METIS Precision Medicine, Novartis, Revolution Medicines, Zymeworks, Seattle Genetics, Sanofi, Menarini, AMGEN, BioMedical Insights, Artemida Pharma, Denali Therapeutics; honoraria for lecture from Roche; research funding from: Zymeworks (Inst), Revolution Medicines (Inst); support for attending meetings from Celgene, Roche, Chugai Pharma, Pfizer; is co-inventor of ‘European patent Application N. 12195182.6 and 12196177.5 titled PDL-1 expression in anti-HER2 therapy’-Roche-Issued (no compensation provided); and is Chair of the Breast Cancer Research Committee of Fondazione Michelangelo. GB has received consulting fees from Roche, AstraZeneca, Novartis, MSD, Sanofi, Daiichi Sankyo, and Exact Sciences; honoraria for speakers’ bureaus from Roche, Pfizer, Astra- Zeneca, Lilly, Novartis, Neopharm Israel, MSD, Chugai, Daiichi Sankyo, EISAI, and Exact Sciences; support for travel, accommodations, expenses from Roche, Pfizer, and AstraZeneca; is co-inventor of ‘European patent Application N. 12195182.6 and 12196177.5 titled “PDL-1 expression in anti-HER2 therapy” -Roche- Issued (no compensation provided); has served on the advisory boards for Pfizer, Roche, Daiichi Sankyo, Lilly, MSD, Novartis, AstraZeneca, Genomic Health, EISAI, Gilead, Seagen.